Terns Pharma successfully shifted its focus after its GLP-1 obesity drug showed underwhelming results. By pivoting to its promising oncology asset for chronic myeloid leukemia, the company dramatically increased its value, culminating in a nearly $7 billion acquisition by Merck. This demonstrates the value of decisively abandoning struggling programs for high-potential ones.

When Artiva pivoted from oncology to autoimmune disease, CEO Fred Aslan faced a significant leadership challenge: every employee had joined with the mission to cure cancer. The transition required re-anchoring the team's motivation to the broader purpose of developing meaningful drugs for areas of high unmet need, successfully navigating a potential culture shock.

Deciding to abandon a profitable product for a nascent one was difficult. The COVID-19 pandemic forced the decision by killing the old product's sales pipeline while accelerating demand for the new one's remote access capabilities, making the pivot clear and necessary overnight.

Facing financial challenges as Platelet Biogenesis, the company pivoted. Instead of creating complex artificial platelets, they now extract the regenerative growth factors from platelet-producing cells. This de-risked the product and focused the platform on a more achievable therapeutic, saving the company.

While Terns' CEO cited "following the data" for their promising CML drug, the decision to de-prioritize metabolic disease was equally influenced by the competitive landscape. She noted the extreme difficulty of competing against larger, well-capitalized players in the obesity market, making the pivot a strategic choice based on relative opportunity and defensibility.

Pivoting isn't just for failing startups; it's a requirement for massive success. Ambitious companies often face 're-founding moments' when their initial product, even if successful, proves insufficient for market-defining scale. This may require risky moves, like competing against your own customers.

Peptilogics shifted from the challenging general antibiotic market to a niche with massive unmet needs after an orthopedic surgeon collaborator called their drug "the greatest thing I've ever seen" for prosthetic joint infections, an application the CEO hadn't even considered.

Hazel's founder frames their major business model change not as a failure, but as finding a better path to the same goal. Their mission was always to increase competition in government procurement. This missionary focus provided the stability and clarity needed to make a difficult but correct product pivot.

PathoQuest's survival depended on a difficult strategic pivot. The company had to abandon its initial, ambitious goal of developing clinical diagnostics for infectious diseases to focus solely on providing QC services to the pharma industry. The CEO admitted that without this tough decision, the company would have failed.